Elmarakeby, Haitham A.
Trukhanov, Pavel S.
Arroyo, Vidal M.
Riaz, Irbaz Bin
Schrag, Deborah
Van Allen, Eliezer M.
Kehl, Kenneth L.
Funding for this research was provided by:
U.S. Department of Defense, CDMRP Award (HT9425-23-1-0023)
Prostate Cancer Foundation
Doris Duke Charitable Foundation (2020080)
U.S. Department of Defense (W81XWH-21-PCRP-DSA)
Mark Foundation Emerging Leader Award
National Cancer Institute (R00CA245899)
Article History
Received: 2 February 2023
Accepted: 7 August 2023
First Online: 2 September 2023
Declarations
:
: The data for this analysis were derived from the EHRs of patients with lung cancer who had genomic profiling performed through the Dana-Farber Cancer Institute (DFCI) PROFILE [CitationRef removed] precision medicine effort or as a standard of care clinical test from June 26, 2013, to July 2, 2018. PROFILE participants consented to medical records review and genomic profiling of their tumor tissue. PROFILE was approved by the Dana-Farber/Harvard Cancer Center Institutional Review Board (protocol #11-104 and #17-000); this supplemental retrospective analysis was declared exempt from review, and informed consent was waived for the standard of care genotyping patients given the minimal risk of data analysis, also by the Dana-Farber/Harvard Cancer Center Institutional Review Board (protocol #16-360). All methods were performed in accordance with the Declaration of Helsinki and approved by the Institutional Review Board at Dana Farber Cancer Institute.
: Not applicable.
: Dr. Kehl reports serving as a consultant/advisor to Aetion, receiving funding from the American Association for Cancer Research related to this work, and receiving honoraria from Roche and IBM. Dr. Schrag reports compensation from JAMA for serving as an Associate Editor and from Pfizer for giving a talk at a symposium. She has received research funding from the American Association for Cancer Research related to this work and research funding from GRAIL for serving as the site-PI of a clinical trial. Unrelated to this work, Dr. Van Allen reports serving in advisory/consulting roles to Tango Therapeutics, Genome Medical, Invitae, Enara Bio, Janssen, Manifold Bio, and Monte Rosa; receiving research support from Novartis and BMS; holding equity in Tango Therapeutics, Genome Medical, Syapse, Enara Bio, Manifold Bio, Microsoft, and Monte Rosa; and receiving travel reimbursement from Roche/Genentech. Pavel Trukhanov reports ownership interest in NoRD Bio. The remaining authors declare no competing interests.